CLX three-lens brief
Evidence-based stock research on CLX. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Underperforming SPY by 29.6pp over 30 days. · Trading at 2% of its 52-week range — deep in the lower band.
- Trading at 2% of its 52-week range — deep in the lower band.
- RSI at 26 — technically oversold.
- Underperforming SPY by 29.6pp over 30 days.
- Analyst mean target $108.24 — 25% above current (17 analysts).
- Debt-to-equity of 4876.1 — balance-sheet-heavy.
CLX closed at $86.68 (-0.49%) as of 2026-05-04. Market cap: $10.48B. P/E (trailing) 14.1. Positives: analyst mean target $108.24 — 25% above current (17 analysts).. Concerns: trading at 2% of its 52-week range — deep in the lower band.; rSI at 26 — technically oversold.. Last quarter: Revenue $1.67B, net income $187.00M, free cash flow $69.13M.
Why three lenses on CLX, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CLXacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CLX" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CLX brief"></iframe>